ASH 2019 | Monitoring disease in high-risk MM: Euroflow with mass spectrometry
Andrew Spencer, MBBS, FRACP FRCPA, DM, Alfred Health-Monash University, Melbourne, Australia, discusses a study evaluating a blood-based strategy for disease burden evaluation; quantitative immunoprecipitation mass spectrometry (QIP MS) and free light chain mass spectrometry (FLC MS) in functional high risk multiple myeloma (MM) patients also undergoing sequential next generation flow-cytometry (EuroFlow platform) measurable residual disease (MRD) evaluation. Prof. Spencer emphasizes that mass spectrometry is a sensitive platform for looking at disease burden and will help clarify which patients need to be evaluated for MRD. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
